Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Net Income: 2018-2025

Historic Net Income for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Sep 2025 value amounting to -$13.4 million.

  • Arcturus Therapeutics Holdings' Net Income fell 94.81% to -$13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.7 million, marking a year-over-year decrease of 6.57%. This contributed to the annual value of -$80.9 million for FY2024, which is 172.30% down from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' Net Income stood at -$13.4 million, which was down 46.49% from -$9.2 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Net Income ranged from a high of $118.6 million in Q4 2022 and a low of -$57.7 million during Q1 2021.
  • Over the past 3 years, Arcturus Therapeutics Holdings' median Net Income value was -$14.1 million (recorded in 2025), while the average stood at -$13.4 million.
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 509.45% in 2021, then soared by 415.16% in 2022.
  • Arcturus Therapeutics Holdings' Net Income (Quarterly) stood at -$37.6 million in 2021, then skyrocketed by 415.16% to $118.6 million in 2022, then tumbled by 109.84% to -$11.7 million in 2023, then plummeted by 156.89% to -$30.0 million in 2024, then tumbled by 94.81% to -$13.4 million in 2025.
  • Its Net Income stands at -$13.4 million for Q3 2025, versus -$9.2 million for Q2 2025 and -$14.1 million for Q1 2025.